日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials

阿托格泮预防性治疗偏头痛的早期疗效:3项随机3期试验的结果

Lipton, Richard B; Gandhi, Pranav; Tassorelli, Cristina; Reuter, Uwe; Harriott, Andrea M; Holle-Lee, Dagny; Gottschalk, Christopher H; Neel, Brian; Liu, Yingyi; Guo, Hua; Stokes, Jonathan; Nagy, Krisztian; Dabruzzo, Brett; Smith, Jonathan H

Mapping Dural and Periosteal SV2C, a Botulinum Toxin A Receptor, in the Mouse.

在小鼠中绘制硬脑膜和骨膜 SV2C(肉毒杆菌毒素 A 受体)的分布图。

Dehghani Anisa, Melo-Carrillo Agustin, Strassman Andrew M, Broide Ron S, Adams Aubrey Manack, Dabruzzo Brett, Brin Mitchell F, Burstein Rami

Correction to: Real‑World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review

更正:阿托格泮联合A型肉毒杆菌毒素预防慢性偏头痛的真实世界安全性和有效性证据:一项回顾性病历审查

Blumenfeld, Andrew M; Mechtler, Laszlo; Cook, Lisa; Rhyne, Christopher; Jenkins, Brian; Hughes, Olivia; Dabruzzo, Brett; Manack Adams, Aubrey; Diamond, Merle

Novel insight into atogepant mechanisms of action in migraine prevention

对阿托格潘特在预防偏头痛中的作用机制的新见解

Melo-Carrillo, Agustin; Strassman, Andrew M; Broide, Ron; Adams, Aubrey; Dabruzzo, Brett; Brin, Mitchell; Burstein, Rami

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial

在随机、双盲、3期PROGRESS试验中,阿托格泮治疗伴或不伴急性药物过度使用的慢性偏头痛的疗效

Goadsby, Peter J; Friedman, Deborah I; Holle-Lee, Dagny; Demarquay, Genevieve; Ashina, Sait; Sakai, Fumihiko; Neel, Brian; Gandhi, Pranav; Dabruzzo, Brett; Smith, Jonathan H; Liu, Yingyi; Trugman, Joel M

Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials

阿托格泮用于预防性治疗偏头痛的安全性和耐受性:四项临床试验汇总数据的回顾性分析

Rizzoli, Paul; Marmura, Michael J; Robblee, Jennifer; McVige, Jennifer; Sacco, Sara; Nahas, Stephanie J; Ailani, Jessica; De Abreu Ferreira, Rosa; Ma, Julia; Smith, Jonathan H; Dabruzzo, Brett; Ashina, Messoud

Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial

阿托格泮治疗发作性偏头痛的持续疗效:一项为期 12 周的随机试验和一项为期 52 周的长期安全性试验的事后分析

Lipton, Richard B; Nahas, Stephanie J; Pozo-Rosich, Patricia; Bilchik, Tanya; McAllister, Peter; Finnegan, Michelle; Liu, Yingyi; Chalermpalanupap, Natty; Dabruzzo, Brett; Dodick, David W

Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review

阿托格泮联合A型肉毒杆菌毒素预防慢性偏头痛的安全性和有效性的真实世界证据:一项回顾性病例分析

Blumenfeld, Andrew M; Mechtler, Laszlo; Cook, Lisa; Rhyne, Christopher; Jenkins, Brian; Hughes, Olivia; Dabruzzo, Brett; Manack Adams, Aubrey; Diamond, Merle

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial

阿托格泮用于成人偏头痛预防的反应率:一项随机临床试验的二次分析

Lipton, Richard B; Pozo-Rosich, Patricia; Blumenfeld, Andrew M; Dodick, David W; McAllister, Peter; Li, Ye; Lu, Kaifeng; Dabruzzo, Brett; Miceli, Rosa; Severt, Lawrence; Finnegan, Michelle; Trugman, Joel M

Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial

阿托格泮预防性治疗偏头痛的疗效时间进程:来自随机、双盲 ADVANCE 试验的结果

Schwedt, Todd J; Lipton, Richard B; Ailani, Jessica; Silberstein, Stephen D; Tassorelli, Cristina; Guo, Hua; Lu, Kaifeng; Dabruzzo, Brett; Miceli, Rosa; Severt, Lawrence; Finnegan, Michelle; Trugman, Joel M